Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020
By Dr. Matthew Watson
CHICAGO, April 16, 2021 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“the Company") (OTCQX: COSM), a vertically integrated, international pharmaceutical company with a proprietary line of branded and generic pharmaceuticals, nutraceuticals, OTC medications and an extensive, established European Union distribution network, today provided a business update and reported financial results for the full year ended December 31, 2020.
Continued here:
Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020
Related Post
- Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B... - April 10th, 2024
- Ultimovacs – Invitation to Business Update on April 17, 2024 - April 10th, 2024
- Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective... - April 10th, 2024
- Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - April 10th, 2024
- Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 - April 10th, 2024
- Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today - April 10th, 2024
- ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024 - April 10th, 2024
- Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - April 10th, 2024
- SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious... - April 10th, 2024
- Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results - April 10th, 2024
- Certara to Report First Quarter 2024 Financial Results on May 7th, 2024 and Participate in the BofA Securities Healthcare Conference - April 10th, 2024
- Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2... - April 10th, 2024
- Frontier Medicines Presents New Data for First-In-Class Dual ON+OFF KRAS G12C Inhibitor FMC-376 at the AACR Annual Meeting - April 10th, 2024
- IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 - April 10th, 2024
- Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300... - April 10th, 2024
- Auron Unveils Preclinical Data Supporting its Lead Program and Ability of its AURIGIN™ Platform to Generate Targeted Cancer Therapies at AACR Annual... - April 10th, 2024
- Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting - April 10th, 2024
- Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024 - April 10th, 2024
- ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients... - April 10th, 2024
- Recce Pharmaceuticals Selected by UK Government Innovation Agency to Participate in AMR Mission 2024 - April 10th, 2024
- AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal... - March 26th, 2024
- Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials - March 26th, 2024
- Gedeon Richter Selects Trial Interactive for Clinical Trial Management - March 26th, 2024
- Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of... - March 26th, 2024
- OXURION announces its presence at the Paris SmallCap event on March 28, 2024. - March 26th, 2024
- Foreløbige tal for 2023 og finansielle forventninger til 2024 - March 26th, 2024
- eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 26th, 2024
- Praxis Precision Medicines to Host PRAX-628 Program Update - March 26th, 2024
- BioCryst to Present at Upcoming Investor Conferences - March 26th, 2024
- NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference - March 26th, 2024
- Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results - March 26th, 2024
- QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system - March 26th, 2024
- Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights - March 26th, 2024
- Agile Therapeutics Announces Delisting from Nasdaq - March 26th, 2024
- Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones - March 26th, 2024
- United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA... - March 26th, 2024
- Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection - March 26th, 2024
- CARBIOS joins Paris Good Fashion to accelerate textile circularity and contribute to more sustainable fashion - March 26th, 2024
- argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia - March 26th, 2024
- Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate - March 26th, 2024
- Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8® - March 18th, 2024
- Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results - March 18th, 2024
- Nuvectis Pharma to Present at the 36th Annual Roth Conference - March 18th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - March 18th, 2024
- Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million - March 18th, 2024
- Avenue Therapeutics Receives Positive Listing Determination from Nasdaq - March 18th, 2024
- AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity - March 18th, 2024
- Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024 - March 18th, 2024
- Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer - March 18th, 2024
- Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement... - March 18th, 2024
- Sanofi: Information concerning the total number of voting rights and shares - February 2024 - March 18th, 2024
- Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc. - March 18th, 2024
- Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - March 18th, 2024
- XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - March 18th, 2024
- Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares - March 18th, 2024
- NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence - March 18th, 2024
- Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - March 18th, 2024
- Financière de Tubize - Annual report 2023 - March 18th, 2024
- Valneva Announces Extension of the Interest-Only Period of Its Debt Facility with Deerfield and OrbiMed - March 18th, 2024
- Idorsia and Viatris successfully close the transaction for the global research and development collaboration - March 18th, 2024
- Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results - March 10th, 2024
- Arbutus to Participate in Two Upcoming Investor Conferences - March 10th, 2024
- SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships - March 10th, 2024
- Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update - March 10th, 2024
- Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early... - March 10th, 2024
- Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights - March 10th, 2024
- DBV Technologies announces filing of 2023 Annual Report on Form 10-K and Universal Registration Document - March 10th, 2024
- Kane Biotech Receives Bioscience Association Manitoba Company of the Year Award - March 10th, 2024
- Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program - March 10th, 2024
- Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of... - March 10th, 2024
- Evn Introduces a Game-Changer in Cannabis Edibles with New Hemp-Derived Live Resin Gummies - March 10th, 2024
- Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease - March 10th, 2024
- NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel - March 10th, 2024
- Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference - March 10th, 2024
- Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates - March 10th, 2024
- Better Choice Company To Effectuate a Reverse Stock Split - March 10th, 2024
- PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update - March 10th, 2024
- Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD... - March 10th, 2024
- Ultimovacs ASA: Mandatory notification of trades by primary insider - March 10th, 2024
- New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction - March 10th, 2024
Global News Feed
Comments Off on Cosmos Holdings Reports Revenue Growth of 40% to a Record $55.4 Million and Achieves Profitability for 2020 |
April 19th, 2021
This author published 5452 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research